Divergent Isoprenoid Biosynthesis Pathways in Staphylococcus Species Constitute a Drug Target for Treating Infections in Companion Animals
ABSTRACT
Staphylococcus species are a leading cause of skin and soft tissue infections in humans and animals, and the antibiotics used to treat these infections are often the same. Methicillin- and multidrug-resistant staphylococcal infections are becoming more common in human and veterinary medicine. From a “One Health” perspective, this overlap in antibiotic use and resistance raises concerns over the potential spread of antibiotic resistance genes. Whole-genome sequencing and comparative genomics analysis revealed that Staphylococcus species use divergent pathways to synthesize isoprenoids. Species frequently associated with skin and soft tissue infections in companion animals, including S. schleiferi and S. pseudintermedius, use the nonmevalonate pathway. In contrast, S. aureus, S. epidermidis, and S. lugdunensis use the mevalonate pathway. The antibiotic fosmidomycin, an inhibitor of the nonmevalonate pathway, was effective in killing canine clinical staphylococcal isolates but had no effect on the growth or survival of S. aureus and S. epidermidis. These data identify an essential metabolic pathway in Staphylococcus that differs among members of this genus and suggest that drugs such as fosmidomycin, which targets enzymes in the nonmevalonate pathway, may be an effective treatment for certain staphylococcal infections.
IMPORTANCE Drug-resistant Staphylococcus species are a major concern in human and veterinary medicine. There is a need for new antibiotics that exhibit a selective effect in treating infections in companion and livestock animals and that would not be used to treat human bacterial infections. We have identified fosmidomycin as an antibiotic that selectively targets certain Staphylococcus species that are often encountered in skin infections in cats and dogs. These findings expand our understanding of Staphylococcus evolution and may have direct implications for treating staphylococcal infections in veterinary medicine.
INTRODUCTION
Staphylococcus infections pose a serious health threat to humans, companion animals, and livestock (1–3). Staphylococcus aureus is a Gram-positive bacterium that can asymptomatically colonize human skin and the anterior nares, but it is also responsible for mild to severe skin and soft tissue infections and life-threatening endocarditis, pneumonia, and sepsis. The Centers for Disease Control and Prevention estimated that in 2014 there were 72,000 invasive methicillin-resistant S. aureus (MRSA) infections in the United States, which resulted in 9,000 deaths (4). Although the prevalence of MRSA carriage in companion animals is low (approximately 0 to 4%) (5, 6) and infections are rare (7), other Staphylococcus species are common commensals and pathogens in veterinary medicine (8). S. schleiferi and S. pseudintermedius are the leading causes of canine and feline skin and ear infections (9); S. hyicus causes high-morbidity skin infections in pigs (10) and osteomyelitis in birds (11), while S. aureus, S. agnetis, and S. chromogenes cause mastitis in cattle and are associated with reduced milk quality (5, 12, 13).
The emergence of drug-resistant Staphylococcus is a global problem (14–21). Drugs such as erythromycin and cephalexin are commonly used to treat infections in both humans and animals, leading to concern that as resistance to shared antibiotics becomes more widespread, zoonotic transmission of either drug-resistant Staphylococcus or horizontal transfer of resistance genes (22) may render these treatments ineffective for both humans and animals. Despite the major animal health burden posed by a range of Staphylococcus species, much of our knowledge of Staphylococcus biology stems from studies on only a handful species that are important causes of human disease. To address this knowledge gap, we have used whole-genome sequencing of S. schleiferi and comparative genomics to identify novel drug targets to treat staphylococcal infections in companion animals.
RESULTS
High-quality genome sequences for S. schleiferi obtained via long-read sequencing technology.
We previously reported the use of single-molecule, real-time sequencing to generate complete genome sequences of four canine clinical isolates of S. schleiferi (23). These isolates represented a spectrum of antibiotic resistance profiles, from susceptible to all tested antibiotics (isolate 2142-05), intermediate resistance (2317-03 and 5909-02), to multidrug resistant (1360-13) (see Table S1 in the supplemental material). The long reads produced by this approach improved the ability to assemble highly repetitive regions of the S. schleiferi genome. For example, rRNA operons represent some of the longest repetitive regions in most bacterial genomes (24), and therefore they pose the biggest challenge for assembly. In addition, clustered, regularly interspaced short palindromic repeat (CRISPR) loci, a type of bacterial adaptive immunity, also pose a challenge to assembly, as they are comprised of a variable number of short, repetitive sequence elements. Our sequencing generated numerous long reads that completely spanned both of these difficult-to-assemble regions of the bacterial genome (Fig. S1a and b). Taken together, these data show that high-quality finished genomes have been generated for this important veterinary pathogen.
Comparative genomic analysis of staphylococcal species.
To better understand the population genetics of Staphylococcus and identify putative drug targets, we compared our S. schleiferi genomes with publicly available complete genome sequences for four other Staphylococcus species. These included S. pseudintermedius, a leading cause of companion animal infections, and S. epidermidis, S. lugdunensis, and S. aureus USA300, important causes of community-acquired infections in humans. Genomes were aligned to strain USA300 via BLAST v2.2.22 (25) and visualized with Brig v0.95 (26) (Fig. 1a). A visual inspection of the circular alignments revealed genomic regions that were present in the human-associated S. aureus strain USA300 but absent from canine-associated species (Fig. 1a, arrows). Similarly, other regions were absent from all species examined except for S. aureus USA300 (Fig. 1a, arrowheads). To more robustly identify genetic pathways differentially abundant among Staphylococcus species, we expanded our analysis to include two to four strains for each of the five species shown in Fig. 1a. In total, genomes from 14 strains were annotated by using Rapid Annotation through Subsystems Technology (RAST) (27), allowing gene membership for 382 subsystems to be compared (see Table S2 in the supplemental material). A total of 147 subsystems were conserved, with an equal number of genes present in each subsystem across all 14 strains examined. In contrast, genes in 235 subsystems were differentially abundant among two or more species.
FIG 1
To identify relationships within the subsystems data, hierarchical clustering was performed to group bacterial strains based on similar subsystems profiles (Fig. 1b, top dendrogram), as well as to group subsystems (Fig. 1b, rows) that were enriched in canonically human-associated species (S. aureus, S. epidermidis, and S. lugdunensis) or canine-associated species (S. schleiferi and S. pseudintermedius). As expected, strains from the same species clustered most closely together (Fig. 1b, top dendrogram). The human- and canine-associated Staphylococcus species segregated, indicating that they differ in their functional gene content.
Differences in virulence factors and metabolic pathways dominate subsystems analysis.
At least three distinct subsystem clusters emerged from our analysis. Cluster 1 consisted of 15 subsystems enriched in all four S. aureus strains but absent from all other species. This subsystem cluster included adhesins and pore-forming cytolysins (Fig. 1d). Given the importance of virulence factors in Staphylococcus biology, we examined these subsystems in more detail. S. aureus isolates contained more than 20 adhesins, while S. epidermidis and S. lugdunensis isolates had between 6 and 8 adhesins and the S. schleiferi and S. pseudintermedius isolates contained 9 to 10 adhesins. Table S3 in the supplemental material includes a list of 23 adhesins and their presence or absence among 14 genomes. One adhesin, staphylocoagulase, activates prothrombin to coagulate blood. Although S. pseudintermedius and S. schleiferi subsp. coagulans (S. schleiferi strain 1360-13) can coagulate blood, our subsystems analysis showed that there were no staphylocoagulase genes (coa) present in the genomes (see Table S3). Consistent with previous studies of S. aureus, we found that S. aureus contains more virulence factors than other Staphylococcus species (28–30). Table S3 shows select adhesins and antimicrobial resistance factors found among the staphylococcal genomes. A surprising finding was that S. schleiferi 1360-13 is methicillin resistant (see Table S1 in the supplemental material), yet a mecA or mecC gene was not found in the genome nor on a plasmid (see Table S3). A recent report documented a case of an S. schleiferi human clinical isolate that was resistant to methicillin yet was penicillin binding protein 2 negative (31). The basis of methicillin resistance in these isolates is not yet understood.
Cluster 2 comprised 15 subsystems that were absent from canine-associated Staphylococcus isolates but which were present across all other species examined (Fig. 1c). Among these subsystems was the mevalonate pathway for isoprenoid biosynthesis. This finding was surprising, given that isoprenoids are an essential class of natural products and that staphylococci have been shown to use the mevalonate pathway for isoprenoid biosynthesis (32, 33). Further examination of the canine-associated Staphylococcus species (cluster 3, 13 subsystems) showed that these species use the nonmevalonate pathway, an alternative route to isoprenoid biosynthesis (Fig. 1e). Taken together, these data suggest that staphylococcal species use different routes to generate isoprenoids.
Fosmidomycin selectively kills bacteria associated with veterinary skin and ear infections.
Isoprenoid biosynthesis is a highly conserved and essential process in bacteria, eukaryotes, and plants (33, 34), and inhibitors have been used to target both the mevalonate and the nonmevalonate pathways. We hypothesized that if S. schleiferi and S. pseudintermedius used the nonmevalonate pathway to synthesize isoprenoids, they should be sensitive to the drug fosmidomycin, a phosphonic acid derivative that blocks the first committed step of the nonmevalonate pathway via inhibition of 1-deoxy-d-xylulose 5-phosphate reductoisomerase (Dxr) (35). To test this hypothesis, S. schleiferi and S. pseudintermedius (canine associated) and S. aureus and S. epidermidis (human associated) were grown on Mueller-Hinton agar plates supplemented with 50 µg/ml fosmidomycin. As expected, S. aureus and S. epidermidis, both of which are reported to use the mevalonate pathway (33), grew in the presence of fosmidomycin. In contrast, fosmidomycin completely restricted growth of S. schleiferi and S. pseudintermedius (Fig. 2a). To expand on this analysis, we used MIC and minimum bactericidal concentration (MBC) assays to quantify fosmidomycin activity against a panel of Staphylococcus strains from the five species evaluated in Fig. 1. While S. aureus, S. lugdunensis, and S. epidermidis grew normally even in the presence of 256 µg/ml of the drug, S. schleiferi and S. pseudintermedius were inhibited by fosmidomycin concentrations as low as 0.5 µg/ml and were killed by concentrations of 4 to 16 µg/ml (Fig. 2b). These results provide a biochemical validation of our comparative genomics data (Fig. 1) and suggest that this antibiotic is active against specific Staphylococcus species.
FIG 2
Divergent isoprenoid biosynthesis in the genus Staphylococcus is associated with host species.
Although many Gram-negative bacteria have been described to use the nonmevalonate pathway (32, 36, 37), S. aureus and other Staphylococcus species have long been cited as examples of bacteria that use the mevalonate pathway (32, 33). This prompted us to expand our bioinformatics analysis beyond the five Staphylococcus species examined thus far to explore isoprenoid biosynthesis more broadly across the genus. The superoxide dismutase (sodA) gene was used to construct a maximum-likelihood phylogenetic tree, and manual curation with KEGG was used to determine which isoprenoid biosynthesis pathway was present in 29 staphylococcal species (Fig. 3). The sodA gene has previously been shown to be a good representative of Staphylococcus phylogeny (38). This analysis showed that the nonmevalonate pathway was frequently used by Staphylococcus species known to cause disease in companion animals and wildlife (Fig. 3, gray box). Use of the nonmevalonate pathway appears to be an ancestral trait, with use of the mevalonate pathway emerging later (Fig. 3, red dot). Staphylococcus species that possess the mevalonate pathway formed a monophyletic group that included many notable human- and primate-associated species, such as S. hominis, S. haemolyticus, S. simiae, and S. aureus (Fig. 3, yellow box). Also included in this clade were animal-associated species, including S. equorum, S. gallinarum, and S. xylosus, which are often associated with horses, chickens, and mice, respectively, as well as S. aureus strain ST398, which is an important cause of disease in livestock.
FIG 3
Lateral gene transfer has been suggested to be common in the evolution of isoprenoid biosynthesis in bacteria (37), and this prompted us to examine the gene membership of both pathways for a range of Staphylococcus species. The mevalonate pathway begins with acetyl coenzyme A (CoA), which undergoes five sequential enzymatic reactions to generate isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), which are then converted to isoprenoids (Fig. 4a, blue). In contrast, the nonmevalonate pathway involves a completely distinct set of seven sequential enzymatic steps to convert pyruvate or glucose-3-phosphate to IPP and DMAPP (Fig. 4a, red).
FIG 4
While S. aureus, S. epidermidis, and S. lugdunensis each possess every gene in the mevalonate pathway, they have also retained some nonmevalonate pathway enzymes, including 2-C-methyl-d-erythritol 4-phosphate cytidylyltransferase (IspD) and 4-diphosphocytidyl-2C-methyl-d-erythritol kinase (IspE) (Fig. 4b; see also Table S4 in the supplemental material). In contrast, canine-associated S. pseudintermediusand S. schleiferi possess all members of the nonmevalonate pathway and completely lack genes of the mevalonate pathway (Fig. 4b; see Table S4). The genomic location of functionally related genes can reflect their evolutionary history. Similar to the Staphylococcus mevalonate pathway (Fig. 4c, red triangles) (33), we found that the nonmevalonate pathway genes were dispersed across the chromosome (Fig. 4c, blue triangles). Taken together, these data argue against a recent lateral transfer of either pathway.
DISCUSSION
The majority of studies examining the metabolism and biology of Staphylococcus have focused on S. aureus. While S. aureus is an important pathogen in humans and animals, there are many other Staphylococcus species of great importance to veterinary medicine. Early biochemical experiments conducted primarily with S. aureus helped to establish a dogma that Staphylococcus uses the mevalonate pathway to synthesize essential isoprenoids. Our data challenge this dogma and show that isoprenoid biosynthesis differs between Staphylococcus species. Given that mammals use the same pathway, it has been assumed that targeting isoprenoid biosynthesis is not a viable strategy to treat staphylococcal bacterial infections in humans or other animals. These data point to inhibitors of the nonmevalonate pathway, such as fosmidomycin, as potential antimicrobials to treat certain Staphylococcus infections in animals, in particular in companion animals where species utilizing the nonmevalonate pathway are a major cause of skin and ear infections.
The main target of fosmidomycin is the Dxr protein, but there is evidence that it can also inhibit a downstream enzyme, IspD, in vitro and in vivo (39). As is the case with any antibiotic, resistance to fosmidomycin could develop in Staphylococcus, either by blocking entry or accumulation of the drug in the bacterium or via mutations in the Dxr binding site, both of which have been reported in other pathogens (40–42). Despite these potential problems, the current clinical literature suggests that fosmidomycin could be a promising drug to treat infections caused by Staphylococcus species that use the nonmevalonate pathway. Fosmidomycin is extremely well-tolerated and exhibits low toxicity in mammals (32). Plasmodium falciparum, the cause of malaria, also synthesizes isoprenoids via the nonmevalonate pathway, and fosmidomycin was shown to be effective in killing the parasite in culture and achieved cure rates of 85 to 100% in clinical trials when administered alone or in combination with clindamycin (43, 44).
Most Gram-negative bacteria synthesize isoprenoids via the nonmevalonate pathway. However, across different bacterial phyla, there are examples of species that use the mevalonate pathway, including Streptococcus, Lactobacillus, Myxococcus, and Borrelia. In addition, some Pseudomonas species, including Pseudomonas mevalonii, are known to use hydroxymethylglutaryl-CoA reductase (the third enzyme of the mevalonate pathway) for degradative functions (45, 46). Only Listeria monocytogenes and a few species of Streptomyces are known to possess both pathways, but in both organisms the nonmevalonate pathway plays the essential role in primary metabolism (37), while the mevalonate pathway is dispensable (47). Based on our data, Staphylococcus constitutes a unique example of a bacterial genus whose species utilize different isoprenoid biosynthesis pathways. Our phylogenetic analysis results (Fig. 3) are consistent with previous evolutionary studies that have suggested that the nonmevalonate pathway is the ancestral pathway in bacteria and the mevalonate pathway was acquired later through lateral gene transfer (34); this is further supported by our finding that deep-branching taxa (such as the S. sciuri and S. intermedius groups) use the nonmevalonate pathway, while the more recently branched taxa (including the S. aureus and S. epidermidis groups) use the mevalonate pathway.
An outstanding question is why Staphylococcus species evolved to use different pathways for isoprenoid synthesis and whether pathway usage influences host range selection. There is abundant literature on virulence factors influencing host range (48), but less is known about the role of bacterial metabolism. Interestingly, among the Staphylococcus species we analyzed, mevalonate pathway usage was associated with species that are found across human, nonhuman primate, and animal hosts. In contrast, nonmevalonate pathway usage was only associated with an animal host range. One possible explanation for this observation may lie in the secondary metabolites produced by these pathways and their interaction with the host immune system: 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate (HMB-PP) is an intermediate of the nonmevalonate pathway and a potent activator of Vγ2/Vδ2 (also called Vγ9/Vδ2) T cells (49). HMB-PP has 1,000 times greater immune stimulatory activity than IPP, the analogous intermediate produced by the mevalonate pathway (49, 50). Vγ2Vδ2 cells make up 1 to 5% of peripheral T cells but expand to >50% and rapidly traffic to barrier surfaces in response to pathogens that produce HMB-PP (51, 52), yet these cells are only found in humans and nonhuman primates. This could lead to a scenario in which mevalonate usage (i.e., by S. aureus) results in a relatively weak Vγ2Vδ2 signal, thereby allowing colonization of human and nonhuman primate skin. Moreover, spread to animals would not be impeded, because these hosts completely lack the Vγ2Vδ2-bearing cells. In contrast, nonmevalonate pathway usage (i.e., by S. schleiferi and S. pseudintermedius) would result in production of the potent Vγ2Vδ2 ligand HMB-PP, but this would only be of consequence if the bacteria were on human or nonhuman primate hosts. Thus, one plausible hypothesis is that nonmevalonate pathway usage by Staphylococcus may contribute to an animal host range restriction, but this remains to be tested. Interestingly, S. schleiferi and S. pseudintermedius were first identified in human infections and are occasionally reported to cause serious human disease, but such cases are primarily observed in infants, the elderly, immunocompromised patients, or as a consequence of medical complications (53–57), perhaps lowering the immunological barrier to transmission.
MATERIALS AND METHODS
Bacterial strains, media, and growth conditions.
Staphylococcus isolates used for biochemical analysis were collected at the Matthew J. Ryan Veterinary Hospital of the University of Pennsylvania. S. schleiferi biochemical identification was carried out on a Microscan Walkaway 40 PC20 Gram-positive combo-panel (Dade Behring, Sacramento, CA). Four banked S. schleiferi strains were selected for whole-genome sequencing: 1360-13, 2142-05, 2317-03, and 5909-02. Table S1 in the supplemental material contains a full list of S. schleiferi strains used in this study and their associated metadata. For biochemical assays, the following clinical isolates were used: S. aureus 3964, S. aureus 3899, S. pseudintermedius 5317, S. pseudintermedius 1168OP, S. epidermidis 1151OP-12, and S. lugdunensis F36680.
DNA purification and sequencing.
S. schleiferi genomic DNA was purified, sequenced, and assembled into complete genomes as previously described (23). Briefly, DNA was extracted from overnight cultures of S. schleiferi isolates by using the Qiagen Genomic Tips kit (Valencia, CA, USA). DNA quantity and quality were assessed using a NanoDrop 1000 spectrophotometer (Thermo Scientific, Pittsburgh, PA) and a Qubit fluorometer (Life Technologies, Grand Island, NY, USA). Agarose gel electrophoresis was used to confirm high-molecular-weight DNA (>50 kb) for single-molecule real-time sequencing on a Pacific Biosciences RSII platform. SMRTbell adapters were ligated, and each strain of S. schleiferi was sequenced on 1 cell with one 120-min movie. A hierarchical genome assembly process (HGAP) was performed for each strain using the HGAP.3 module (58). The genome was closed using manual refinement.
Comparative genomics.
For comparative genome analyses, 14 sequences from GenBank were retrieved for the following organisms: S. schleiferi 1360-13 (accession number CP009470 ), S. schleiferi 2142-05 (CP009762 ), S. schleiferi 5909-02 (CP009676 ), S. schleiferi 2317-03 (GenBank: CP010309 ), S. pseudintermedius HKU10-03 (NC_014925.1 ), S. pseudintermedius ED99 (NC_017568 ), S. lugdunensis HKU09-01 (CP001837 ), S. lugdunensis N920143 (FR870271.1 ), S. epidermidis ATCC 12228 (NC_004461 ), S. epidermidis RP62A (NC_002976.3 ), S. aureus subspecies aureus ST398 (NC_017333 ), S. aureus subspecies aureus USA300_FPR3757 (NC_007793 ), S. aureus subspecies aureus COL (NC_002951 ), and S. aureus subspecies aureus NCTC 8325 (NC_007795 ) were downloaded from NCBI (ftp://ftp.ncbi.nlm.nih.gov ). Five circular, whole genomes were aligned using the BLAST Ring Image Generator (BRIG) version 0.95 (26) and the Basic Local Alignment Search Tool (BLAST, v. 2/2/22) (25). Functional gene categories were determined with the Rapid Annotation using Subsystem Technology (RAST) v. 2.0 (27) and FigFam v. 70 programs. Subsystems with a standard deviation of zero among species were removed. The remaining differentially abundant subsystems were clustered by a Pearson correlation, and the bacterial species were clustered by a Spearman correlation using the hclust function in R (v. 3.2.0) (59) to reveal species-specific subsystem clusters. The cutree function in R was used to identify groups with similar subsystem abundance profiles.
Antibiotic susceptibility assays.
The MICs of various antimicrobials (amoxicillin-clavulanic acid, ampicillin, cefazolin, chloramphenicol, ciprofloxacin, clindamycin, erythromycin, gentamicin, imipenem, oxacillin, penicillin, rifampin, tetracycline, trimethoprim-sulfamethoxazole, and vancomycin) were tested via broth microdilution on a Microscan Walkaway 40 PC20 Gram-positive combo-panel (Dade Behring, Sacramento, CA). Fosmidomycin MIC assays were performed following clinical laboratory standards (60). Fosmidomycin (Sigma, St. Louis, MO, USA) was filter sterilized with a 0.2-mm filter (Pall Corporation, Ann Arbor, MI, USA) and was serially 2-fold diluted for a concentration range of 40.96 to 0.25 µg/ml. Tubes containing 1 ml Mueller-Hinton broth (Sigma) were inoculated with 5 × 105 CFU/ml. A 50-μl aliquot of the appropriate fosmidomycin concentration was added to each tube containing the starter culture and was incubated at 37°C overnight with shaking at 250 rpm for 18 to 20 h. The MICs were determined by visual inspection. The MBC was determined by plating 200 µl of the drug-treated cultures onto Mueller-Hinton agar plates (Remel, Lenexa, MA, USA). The lowest concentration at which there was no growth after a 24-h incubation at 37°C was determined to be the MBC. For the plate-based fosmidomycin growth assay, overnight cultures of Staphylococcus species grown in Mueller-Hinton broth were subcultured to Mueller-Hinton agar plates containing 50 µg/ml fosmidomycin and were incubated for 24 h at 37°C. All assays were performed and the results were interpreted using Clinical and Laboratory Standards Institute guidelines (60).
Phylogenetic tree construction and metabolic pathway comparisons.
Gene sequences of sodA from 29 staphylococcal species were downloaded from NCBI. The Web-based tool Phylogeny.fr (61) was used to construct a phylogenetic tree from a sodA gene multiple-sequence alignment, and Macrococcus caseolyticus was set as the outgroup. Sequences were aligned with Muscle v3.7 (62), poorly aligned regions were removed using Gblocks v0.91b (63), and the phylogenetic tree was reconstructed using the maximum likelihood method implemented in PhyML v3.0 (64). Tree rendering was performed using TreeDyn v198.3 (65), and bootstrap values are indicated on the branches. Metabolic pathway reconstructions of each strain were compared in silico using the terpenoid backbone biosynthesis pathway from KEGG (66, 67).
ACKNOWLEDGMENTS
We thank Meghan Davis, Stephen Cole, Kathleen O’Shea, and Kristen Constantine for assistance with bacterial growth and helpful discussions.
A.M.M. purified genomic DNA, assembled the genome sequences, analyzed sequence and subsystems data, performed comparative genomics, performed all bacterial growth and antibiotic assays, and wrote the manuscript. C.L.C. collected S. schleiferi clinical samples. S.C.R. isolated the Staphylococcus clinical isolates, performed all phenotypic testing of the strains, and archived them in a collection held at −80°C. D.P.B. analyzed subsystems data and wrote the manuscript. A.M.M., C.L.C., D.O.M., S.C.L., and D.P.B. conceived of the study, edited the manuscript, gave approval for publication, and agreed to be accountable for the work.
Supplemental Material
REFERENCES
1.
Kawakami T, Shibata S, Murayama N, Nagata M, Nishifuji K, Iwasaki T, and Fukata T. 2010. Antimicrobial susceptibility and methicillin resistance in Staphylococcus pseudintermedius and Staphylococcus schleiferi subsp. coagulans isolated from dogs with pyoderma in Japan. J Vet Med Sci72:1615–1619.
2.
Cain CL, Morris DO, and Rankin SC. 2011. Clinical characterization of Staphylococcus schleiferi infections and identification of risk factors for acquisition of oxacillin-resistant strains in dogs: 225 cases (2003–2009). J Am Vet Med Assoc239:1566–1573.
3.
Cain CL. 2013. Antimicrobial resistance in staphylococci in small animals. Vet Clin North Am Small Anim Pract43:19–40.
4.
Centers for Disease Control and Prevention. 2014. ABCs Report: methicillin-resistant Staphylococcus aureus, 2014. Centers for Disease Control and Prevention, Atlanta, GA.
5.
Weese JS. 2010. Methicillin-resistant Staphylococcus aureus in animals. ILAR J51:233–244.
6.
Loeffler A, Pfeiffer DU, Lindsay JA, Soares Magalhães RJ, and Lloyd DH. 2011. Prevalence of and risk factors for MRSA carriage in companion animals: a survey of dogs, cats and horses. Epidemiol Infect139:1019–1028.
7.
Davis MF, Misic AM, Morris DO, Moss JT, Tolomeo P, Beiting DP, Nachamkin I, Lautenbach E, and Rankin SC. 2015. Genome sequencing reveals strain dynamics of methicillin-resistant Staphylococcus aureus in the same household in the context of clinical disease in a person and a dog. Vet Microbiol180:304–307.
8.
May ER, Hnilica KA, Frank LA, Jones RD, and Bemis DA. 2005. Isolation of Staphylococcus schleiferi from healthy dogs and dogs with otitis, pyoderma, or both. J Am Vet Med Assoc227:928–931.
9.
Davis MF, Cain CL, Brazil AM, and Rankin SC. 2013. Two coagulase-negative staphylococci emerging as potential zoonotic pathogens: wolves in sheep’s clothing?Front Microbiol4:123.
10.
Foster AP. 2012. Staphylococcal skin disease in livestock. Vet Dermatol23:342–351.
11.
Maier K, Fischer D, Hartmann A, Kershaw O, Prenger-Berninghoff E, Pendl H, Schmidt MJ, and Lierz M. 2015. Vertebral osteomyelitis and septic arthritis associated with Staphylococcus hyicus in a juvenile peregrine falcon (Falco peregrinus). J Avian Med Surg29:216–223.
12.
Pyörälä S and Taponen S. 2009. Coagulase-negative staphylococci-emerging mastitis pathogens. Vet Microbiol134:3–8.
13.
Taponen S, Supré K, Piessens V, Van Coillie E, De Vliegher S, and Koort JM. 2012. Staphylococcus agnetis sp. nov., a coagulase-variable species from bovine subclinical and mild clinical mastitis. Int J Syst Evol Microbiol62:61–65.
14.
Bramble M, Morris D, Tolomeo P, and Lautenbach E. 2011. Potential role of pet animals in household transmission of methicillin-resistant Staphylococcus aureus: a narrative review. Vector Borne Zoonotic Dis11:617–620.
15.
Rutland BE, Weese JS, Bolin C, Au J, and Malani AN. 2009. Human-to-dog transmission of methicillin-resistant Staphylococcus aureus. Emerg Infect Dis15:1328–1330.
16.
Verkade E, Kluytmans-van den Bergh M, van Benthem B, van Cleef B, van Rijen M, Bosch T, Schouls L, and Kluytmans J. 2014. Transmission of methicillin-resistant Staphylococcus aureus CC398 from livestock veterinarians to their household members. PLoS One9:e100823.
17.
Loeffler A, Boag AK, Sung J, Lindsay JA, Guardabassi L, Dalsgaard A, Smith H, Stevens KB, and Lloyd DH. 2005. Prevalence of methicillin-resistant Staphylococcus aureus among staff and pets in a small animal referral hospital in the UK. J Antimicrob Chemother56:692–697.
18.
Morris DO, Rook KA, Shofer FS, and Rankin SC. 2006. Screening of Staphylococcus aureus, Staphylococcus intermedius, and Staphylococcus schleiferi isolates obtained from small companion animals for antimicrobial resistance: a retrospective review of 749 isolates (2003–04). Vet Dermatol17:332–337.
19.
Van Duijkeren E, Wolfhagen MJ, Box AT, Heck ME, Wannet WJ, and Fluit AC. 2004. Human-to-dog transmission of methicillin-resistant Staphylococcus aureus. Emerg Infect Dis10:2235–2237.
20.
Fitzgerald JR. 2012. Livestock-associated Staphylococcus aureus: origin, evolution and public health threat. Trends Microbiol20:192–198.
21.
Fluit AC. 2012. Livestock-associated Staphylococcus aureus. Clin Microbiol Infect18:735–744.
22.
Chambers HF and Deleo FR. 2009. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol7:629–641.
23.
Misic AM, Cain CL, Morris DO, Rankin SC, and Beiting DP. 2015. Complete genome sequence and methylome of Staphylococcus schleiferi, an important cause of skin and ear infections in veterinary medicine. Genome Announc3:e01011-15.
24.
Hill CW. 1999. Large genomic sequence repetitions in bacteria: lessons from rRNA operons and Rhs elements. Res Microbiol150:665–674.
25.
Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, and Madden TL. 2009. BLAST+: architecture and applications. BMC Bioinformatics10:421.
26.
Alikhan NF, Petty NK, Ben Zakour NL, and Beatson SA. 2011. BLAST ring image generator (Brig): simple prokaryote genome comparisons. BMC Genomics12:402.
27.
Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, Formsma K, Gerdes S, Glass EM, Kubal M, Meyer F, Olsen GJ, Olson R, Osterman AL, Overbeek RA, McNeil LK, Paarmann D, Paczian T, Parrello B, Pusch GD, Reich C, Stevens R, Vassieva O, Vonstein V, Wilke A, and Zagnitko O. 2008. The RAST server: rapid annotations using subsystems technology. BMC Genomics9:75.
28.
Powers ME and Bubeck Wardenburg J. 2014. Igniting the fire: Staphylococcus aureus virulence factors in the pathogenesis of sepsis. PLoS Pathog10:e1003871.
29.
Lowy FD. 1998. Staphylococcus aureus infections. N Engl J Med339:520–532.
30.
Schlievert PM. 1993. Role of superantigens in human disease. J Infect Dis167:997–1002.
31.
Merchant C, Villanueva DD, Lalani I, Eng M, and Kang Y. 2016. PBP-2 negative methicillin resistant Staphylococcus schleiferi bacteremia from a prostate abscess: an unusual occurrence. Case Rep Infect Dis2016:8979656.
32.
Odom AR. 2011. Five questions about non-mevalonate isoprenoid biosynthesis. PLoS Pathog7:e1002323.
33.
Wilding EI, Brown JR, Bryant AP, Chalker AF, Holmes DJ, Ingraham KA, Iordanescu S, So CY, Rosenberg M, and Gwynn MN. 2000. Identification, evolution, and essentiality of the mevalonate pathway for isopentenyl diphosphate biosynthesis in gram-positive cocci. J Bacteriol182:4319–4327.
34.
Lange BM, Rujan T, Martin W, and Croteau R. 2000. Isoprenoid biosynthesis: the evolution of two ancient and distinct pathways across genomes. Proc Natl Acad Sci U S A97:13172–13177.
35.
Steinbacher S, Kaiser J, Eisenreich W, Huber R, Bacher A, and Rohdich F. 2003. Structural basis of fosmidomycin action revealed by the complex with 2-C-methyl-d-erythritol 4-phosphate synthase (IspC). Implications for the catalytic mechanism and anti-malaria drug development. J Biol Chem278:18401–18407.
36.
Heuston S, Begley M, Gahan CG, and Hill C. 2012. Isoprenoid biosynthesis in bacterial pathogens. Microbiology158:1389–1401.
37.
Boucher Y and Doolittle WF. 2000. The role of lateral gene transfer in the evolution of isoprenoid biosynthesis pathways. Mol Microbiol37:703–716.
38.
Poyart C, Quesne G, Boumaila C, and Trieu-Cuot P. 2001. Rapid and accurate species-level identification of coagulase-negative staphylococci by using the sodA gene as a target. J Clin Microbiol39:4296–4301.
39.
Zhang B, Watts KM, Hodge D, Kemp LM, Hunstad DA, Hicks LM, and Odom AR. 2011. A second target of the antimalarial and antibacterial agent fosmidomycin revealed by cellular metabolic profiling. Biochemistry50:3570–3577.
40.
Armstrong CM, Meyers DJ, Imlay LS, Freel Meyers C, and Odom AR. 2015. Resistance to the antimicrobial agent fosmidomycin and an FR900098 prodrug through mutations in the deoxyxylulose phosphate reductoisomerase gene (dxr). Antimicrob Agents Chemother59:5511–5519.
41.
Brown AC and Parish T. 2008. Dxr is essential in Mycobacterium tuberculosis and fosmidomycin resistance is due to a lack of uptake. BMC Microbiol8:78.
42.
Nair SC, Brooks CF, Goodman CD, Sturm A, Strurm A, McFadden GI, Sundriyal S, Anglin JL, Song Y, Moreno SN, and Striepen B. 2011. Apicoplast isoprenoid precursor synthesis and the molecular basis of fosmidomycin resistance in Toxoplasma gondii. J Exp Med208:1547–1559.
43.
Borrmann S, Issifou S, Esser G, Adegnika AA, Ramharter M, Matsiegui PB, Oyakhirome S, Mawili-Mboumba DP, Missinou MA, Kun JF, Jomaa H, and Kremsner PG. 2004. Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria. J Infect Dis190:1534–1540.
44.
Missinou MA, Borrmann S, Schindler A, Issifou S, Adegnika AA, Matsiegui PB, Binder R, Lell B, Wiesner J, Baranek T, Jomaa H, and Kremsner PG. 2002. Fosmidomycin for malaria. Lancet360:1941–1942.
45.
Beach MJ and Rodwell VW. 1989. Cloning, sequencing, and overexpression of mvaA, which encodes Pseudomonas mevalonii 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Bacteriol171:2994–3001.
46.
Scher DS and Rodwell VW. 1989. 3-Hydroxy-3-methylglutaryl coenzyme A lyase from Pseudomonas mevalonii. Biochim Biophys Acta1003:321–326.
47.
Begley M, Bron PA, Heuston S, Casey PG, Englert N, Wiesner J, Jomaa H, Gahan CG, and Hill C. 2008. Analysis of the isoprenoid biosynthesis pathways in Listeria monocytogenes reveals a role for the alternative 2-C-methyl-d-erythritol 4-phosphate pathway in murine infection. Infect Immun76:5392–5401.
48.
Sung JM, Lloyd DH, and Lindsay JA. 2008. Staphylococcus aureus host specificity: comparative genomics of human versus animal isolates by multi-strain microarray. Microbiology154:1949–1959.
49.
Hintz M, Reichenberg A, Altincicek B, Bahr U, Gschwind RM, Kollas AK, Beck E, Wiesner J, Eberl M, and Jomaa H. 2001. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human gammadelta T cells in Escherichia coli. FEBS Lett509:317–322.
50.
Chen ZW. 2013. Multifunctional immune responses of HMBPP-specific Vγ2Vδ2 T cells in M. tuberculosis and other infections. Cell Mol Immunol10:58–64.
51.
Huang D, Shen Y, Qiu L, Chen CY, Shen L, Estep J, Hunt R, Vasconcelos D, Du G, Aye P, Lackner AA, Larsen MH, Jacobs WR Jr., Haynes BF, Letvin NL, and Chen ZW. 2008. Immune distribution and localization of phosphoantigen-specific Vgamma2Vdelta2 T cells in lymphoid and nonlymphoid tissues in Mycobacterium tuberculosis infection. Infect Immun76:426–436.
52.
Ali Z, Shao L, Halliday L, Reichenberg A, Hintz M, Jomaa H, and Chen ZW. 2007. Prolonged (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate-driven antimicrobial and cytotoxic responses of pulmonary and systemic Vgamma2Vdelta2 T cells in macaques. J Immunol179:8287–8296.
53.
Kumar D, Cawley JJ, Irizarry-Alvarado JM, Alvarez A, and Alvarez S. 2007. Case of Staphylococcus schleiferi subspecies coagulans endocarditis and metastatic infection in an immune compromised host. Transpl Infect Dis9:336–338.
54.
Jindal A, Shivpuri D, and Sood S. 2015. Staphylococcus schleiferi meningitis in a child. Pediatr Infect Dis J34:329.
55.
Thawabi M, Jerome M, Slim J, Shamoon F, and Boghossian J. 2015. Pericardial effusion and sepsis caused by Staphylococcus schleiferi. J Infect Public Health8:392–393.
56.
Van Hoovels L, Vankeerberghen A, Boel A, Van Vaerenbergh K, and De Beenhouwer H. 2006. First case of Staphylococcus pseudintermedius infection in a human. J Clin Microbiol44:4609–4612.
57.
Kuan EC, Yoon AJ, Vijayan T, Humphries RM, and Suh JD. 2016. Canine Staphylococcus pseudintermedius sinonasal infection in human hosts. Int Forum Allergy Rhinol6:710–715.
58.
Chin CS, Alexander DH, Marks P, Klammer AA, Drake J, Heiner C, Clum A, Copeland A, Huddleston J, Eichler EE, Turner SW, and Korlach J. 2013. Nonhybrid, finished microbial genome assemblies from long-read SMRT sequencing data. Nat Methods10:563–569.
59.
R Development Core Team. 2010. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
60.
CLSI. 2013. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals. Approved standard, 4th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
61.
Dereeper A, Guignon V, Blanc G, Audic S, Buffet S, Chevenet F, Dufayard JF, Guindon S, Lefort V, Lescot M, Claverie JM, and Gascuel O. 2008. Phylogeny.fr: robust phylogenetic analysis for the non-specialist. Nucleic Acids Res36:W465–W469.
62.
Edgar RC. 2004. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res32:1792–1797.
63.
Castresana J. 2000. Selection of conserved blocks from multiple alignments for their use in phylogenetic analysis. Mol Biol Evol17:540–552.
64.
Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, and Gascuel O. 2010. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol59:307–321.
65.
Chevenet F, Brun C, Bañuls AL, Jacq B, and Christen R. 2006. TreeDyn: towards dynamic graphics and annotations for analyses of trees. BMC Bioinformatics7:439.
66.
Kanehisa M and Goto S. 2000. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res28:27–30.
67.
Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, and Tanabe M. 2014. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res42:D199–D205.
Information & Contributors
Information
Published In
mSphere
Volume 1 • Number 5 • 26 October 2016
eLocator: 10.1128/msphere.00258-16
Editor: Paul D. Fey, University of Nebraska Medical Center
PubMed: 27704053
Copyright
© 2016 Misic et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license .
History
Received: 26 August 2016
Accepted: 6 September 2016
Published online: 28 September 2016
Keywords:
Contributors
Editor
Paul D. Fey
Editor
University of Nebraska Medical Center
Metrics & Citations
Metrics
Note:
- For recently published articles, the TOTAL download count will appear as zero until a new month starts.
- There is a 3- to 4-day delay in article usage, so article usage will not appear immediately after publication.
- Citation counts come from the Crossref Cited by service.
Citations
Citation
2016.
Divergent Isoprenoid Biosynthesis Pathways in Staphylococcus Species Constitute a Drug Target for Treating Infections in Companion Animals. mSphere
1:10.1128/msphere.00258-16.
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.